Assessing the Risk of Bleeding in Patients with non-valvular Atrial Fibrillation [AF] Treated with a DOAC [NOAC]:
The ABH Score
The ABH Score
Introduction:
The ABH score is a clinical prediction rule for assessing the bleeding risk in patients with Atrial Fibrillation [AF] treated with a DOAC [or NOAC]. In the initial score, 10 variables were analysed - see below. A simplified version of the algorithm was subsequently developed using three variables: Age, a history of bleeding and non-bleeding related hospitalisation in the preceding 12 months - see ABH Score - Simplified.
Drugs used in the study from which the algorithm was derived were:
- Apixaban 2.5 mg or 5 mg
- Rivaroxaban 15 mg or 20 mg
- Dabigatran 110 mg or 150 mg.
Edoxaban was not approved for stroke prevention in AF at the time of the study.
ABH Score - Original